Nearly one-third of patients undergoing multidisciplinary review for inpatient chemotherapy died within 30 days of request, highlighting the medical complexity of this population of patients.
Abstract
603
Background:
Inpatient chemotherapy is frequently administered to hospitalized patients with advanced solid tumor malignancies and has been associated with poor outcomes and high resource utilization. A quality improvement intervention established mandatory multidisciplinary review for all inpatient solid tumor chemotherapy requests at our institution. We sought to characterize the clinical outcomes of patients undergoing evaluation after implementation of this review process.
Methods:
We performed a retrospective review of inpatient chemotherapy requests for patients with solid tumors submitted at a tertiary academic medical center between April 2024 and January 2026. Demographic, clinical, laboratory, and treatment-related data were collected, including infection and functional status, treatment delivery (administered vs. not administered), discharge disposition, mortality, and hospice utilization. Infection status was characterized by objective imaging findings or positive microbiological culture data at the time of chemotherapy request. Functional status was abstracted from physical therapy documentation and characterized as independent ambulation, minimal/moderate assistance, maximal assistance, or not assessed/declined. Descriptive statistics were used to summarize patient characteristics and outcomes. The primary outcome was 30-day mortality from the date of inpatient chemotherapy request.
Results:
Out of 144 unique inpatient chemotherapy requests for 133 patients, 96 (66.7%) were approved, while 46 (32.4%) were denied. Among approved requests, chemotherapy was delivered during hospitalization in 81 patients (82.7%) and not delivered in 17 (17.3%). Thirty-day mortality for the overall cohort was 31.2% (44/141). Patients with approved requests had substantially lower 30-day mortality than those with denied requests (23/96 [24.0%] vs. 21/45 [46.7%]). Active infection was associated with 30-day mortality of 48.5% (16/33), elevated bilirubin >1.5x the upper limit of normal with 56.3% (9/16), and maximal assistance with ambulation with 73.3% (11/15).
Conclusions:
Nearly one-third of patients undergoing multidisciplinary review for inpatient chemotherapy died within 30 days of request, highlighting the medical complexity of this population. Patients whose requests were denied experienced substantially higher short-term mortality than approved patients, suggesting the review process identifies individuals at particularly high risk for poor outcomes. Active infection, hyperbilirubinemia, and severe functional impairment were associated with especially high 30-day mortality and may represent objective factors for consideration in future refinement of inpatient chemotherapy review criteria.
596
Background:
Inpatient chemotherapy for gastrointestinal (GI) malignancies is used selectively for patients with urgent clinical needs or barriers to outpatient treatment, but indications, outcomes, and predictors of early mortality remain poorly defined. We characterized the clinical drivers and short-term...
A. Barabrah, M. Overman, Lian-Chun Xiao et al.· JCO Oncology Practice· 0 citations
289
Background:
Chemotherapy near the end of life carries limited clinical benefit. We evaluated outcomes of patients with solid organ malignancies who received inpatient cytotoxic chemotherapy at a tertiary cancer center.
Methods:
We performed a retrospective study of adults with solid organ malignancies who...
Adeel Arshad, P. Bhateja, Alyssa Antonini et al.· JCO Oncology Practice· 0 citations
The findings support the incorporation of PS assessment into routine oncology practice to identify patients who may benefit from targeted supportive care strategies and closer monitoring, supporting proactive care delivery within high-quality oncology programs.
Victória Santos Marques Pereira, Carolline Damas de Andrade Oliveira, Thays Andreza So Vale da Fonseca et al.· JCO Oncology Practice· 0 citations
551
Background:
Patients with newly diagnosed thoracic malignancies frequently experience delays in diagnosis and treatment initiation, particularly during transitions from inpatient to outpatient oncologic care. Geographic barriers and limited access to specialty services may contribute to treatment delays. We...
Background: Patients with hematologic malignancies frequently receive more aggressive end-of-life care and are less likely to receive timely palliative care than those with solid tumors. There is still little data, though, comparing the short-term outcomes of patients later admitted to inpatient palliative care units w...
W. A. Bokhari, Sumaia A. Felimban, S. M. Aljunaid· Cureus· 0 citations
67
Background:
Across the US, hospitalists increasingly manage solid tumor inpatients, yet the role of primary oncologists in this model is often undefined. At MD Anderson Cancer Center, consult rates by oncology services vary by more than two-fold across the four hospitalist-managed solid tumor departments. Pr...
K. Adelson, L. Pantoja, L. Jackson et al.· JCO Oncology Practice· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.